Probiotics for preventing and treating nosocomial infections

Review of current evidence and recommendations

Warren Isakow, Lee E. Morrow, Marin H. Kollef

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Objective: To review the available clinical data supporting the use of probiotics in preventing and treating serious nosocomial infections. Data source: A Medline database from 1996 to July 2006 and references from identified articles were used to perform a literature search relating to the clinical applications of probiotics in preventing and treating Clostridium difficile-associated diarrhea (CDD) and prevention of hospital-associated pneumonia (HAP). Conclusion: Nosocomial infections like HAP and CDD contribute significantly to health-care costs in the United States. These clinical problems are associated with prolonged hospital stays and increased mortality in critically ill patients. The emergence of multidrug-resistant pathogens in cases of HAP and the recent description of an epidemic, toxin gene-variant strain of C difficile, combined with the anticipated lack of new antimicrobial agents in the near future emphasize the need for new, innovative strategies to prevent and treat these diseases. Probiotics normally function as colonizers and contribute to the overall health of their hosts by multiple mechanisms including immune and antibacterial effects. There is no current clinical evidence to support the use of probiotics to restore the normal human flora in critically ill patients and reduce HAP rates. Probiotics can prevent episodes of antibiotic-associated diarrhea, but their utility in treating and preventing CDD requires demonstration of benefit in multicenter clinical trials, preferably sponsored by the National Institutes of Health.

Original languageEnglish
Pages (from-to)286-294
Number of pages9
JournalChest
Volume132
Issue number1
DOIs
StatePublished - Jul 2007

Fingerprint

Probiotics
Cross Infection
Clostridium difficile
Diarrhea
Pneumonia
Critical Illness
Information Storage and Retrieval
National Institutes of Health (U.S.)
Anti-Infective Agents
Health Care Costs
Multicenter Studies
Length of Stay
Clinical Trials
Databases
Anti-Bacterial Agents
Mortality
Health
Genes

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Probiotics for preventing and treating nosocomial infections : Review of current evidence and recommendations. / Isakow, Warren; Morrow, Lee E.; Kollef, Marin H.

In: Chest, Vol. 132, No. 1, 07.2007, p. 286-294.

Research output: Contribution to journalReview article

@article{0f89aa92234b460c82237967710e72e5,
title = "Probiotics for preventing and treating nosocomial infections: Review of current evidence and recommendations",
abstract = "Objective: To review the available clinical data supporting the use of probiotics in preventing and treating serious nosocomial infections. Data source: A Medline database from 1996 to July 2006 and references from identified articles were used to perform a literature search relating to the clinical applications of probiotics in preventing and treating Clostridium difficile-associated diarrhea (CDD) and prevention of hospital-associated pneumonia (HAP). Conclusion: Nosocomial infections like HAP and CDD contribute significantly to health-care costs in the United States. These clinical problems are associated with prolonged hospital stays and increased mortality in critically ill patients. The emergence of multidrug-resistant pathogens in cases of HAP and the recent description of an epidemic, toxin gene-variant strain of C difficile, combined with the anticipated lack of new antimicrobial agents in the near future emphasize the need for new, innovative strategies to prevent and treat these diseases. Probiotics normally function as colonizers and contribute to the overall health of their hosts by multiple mechanisms including immune and antibacterial effects. There is no current clinical evidence to support the use of probiotics to restore the normal human flora in critically ill patients and reduce HAP rates. Probiotics can prevent episodes of antibiotic-associated diarrhea, but their utility in treating and preventing CDD requires demonstration of benefit in multicenter clinical trials, preferably sponsored by the National Institutes of Health.",
author = "Warren Isakow and Morrow, {Lee E.} and Kollef, {Marin H.}",
year = "2007",
month = "7",
doi = "10.1378/chest.06-2156",
language = "English",
volume = "132",
pages = "286--294",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Probiotics for preventing and treating nosocomial infections

T2 - Review of current evidence and recommendations

AU - Isakow, Warren

AU - Morrow, Lee E.

AU - Kollef, Marin H.

PY - 2007/7

Y1 - 2007/7

N2 - Objective: To review the available clinical data supporting the use of probiotics in preventing and treating serious nosocomial infections. Data source: A Medline database from 1996 to July 2006 and references from identified articles were used to perform a literature search relating to the clinical applications of probiotics in preventing and treating Clostridium difficile-associated diarrhea (CDD) and prevention of hospital-associated pneumonia (HAP). Conclusion: Nosocomial infections like HAP and CDD contribute significantly to health-care costs in the United States. These clinical problems are associated with prolonged hospital stays and increased mortality in critically ill patients. The emergence of multidrug-resistant pathogens in cases of HAP and the recent description of an epidemic, toxin gene-variant strain of C difficile, combined with the anticipated lack of new antimicrobial agents in the near future emphasize the need for new, innovative strategies to prevent and treat these diseases. Probiotics normally function as colonizers and contribute to the overall health of their hosts by multiple mechanisms including immune and antibacterial effects. There is no current clinical evidence to support the use of probiotics to restore the normal human flora in critically ill patients and reduce HAP rates. Probiotics can prevent episodes of antibiotic-associated diarrhea, but their utility in treating and preventing CDD requires demonstration of benefit in multicenter clinical trials, preferably sponsored by the National Institutes of Health.

AB - Objective: To review the available clinical data supporting the use of probiotics in preventing and treating serious nosocomial infections. Data source: A Medline database from 1996 to July 2006 and references from identified articles were used to perform a literature search relating to the clinical applications of probiotics in preventing and treating Clostridium difficile-associated diarrhea (CDD) and prevention of hospital-associated pneumonia (HAP). Conclusion: Nosocomial infections like HAP and CDD contribute significantly to health-care costs in the United States. These clinical problems are associated with prolonged hospital stays and increased mortality in critically ill patients. The emergence of multidrug-resistant pathogens in cases of HAP and the recent description of an epidemic, toxin gene-variant strain of C difficile, combined with the anticipated lack of new antimicrobial agents in the near future emphasize the need for new, innovative strategies to prevent and treat these diseases. Probiotics normally function as colonizers and contribute to the overall health of their hosts by multiple mechanisms including immune and antibacterial effects. There is no current clinical evidence to support the use of probiotics to restore the normal human flora in critically ill patients and reduce HAP rates. Probiotics can prevent episodes of antibiotic-associated diarrhea, but their utility in treating and preventing CDD requires demonstration of benefit in multicenter clinical trials, preferably sponsored by the National Institutes of Health.

UR - http://www.scopus.com/inward/record.url?scp=34447543101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447543101&partnerID=8YFLogxK

U2 - 10.1378/chest.06-2156

DO - 10.1378/chest.06-2156

M3 - Review article

VL - 132

SP - 286

EP - 294

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -